Meta-analysis of 50 trials confirms semaglutide reduces mortality but increases GI side effects | Research

The takeaway

TSA-confirmed meta-analysis of 50 trials (54,972 patients) shows semaglutide reduces all-cause mortality (RR 0.85), serious adverse events, and MI, while increasing nausea (3x), vomiting (4x), and diarrhea (1.9x).

15% mortality reduction confirmed
Trial Sequential Analysis confirms semaglutide saves lives (RR 0.85) across 50 trials, though GI side effects (3-4x increased) require management

What the researchers found

Mortality RR 0.85 (95% CI 0.79-0.91, I²=0%). Reduced SAEs and MI. Increased nausea RR 3.00, vomiting RR 4.12, diarrhea RR 1.88. All confirmed by TSA. 50 trials, 54,972 participants.

Why it matters

This is the most comprehensive safety analysis of semaglutide to date. While confirming mortality and cardiovascular benefits, it quantifies the GI side effect burden—essential information for prescribing decisions and patient counseling.

How the study worked

Systematic review of 6 databases through March 2025. 50 RCTs, 54,972 participants. Meta-analysis with Trial Sequential Analysis. Cochrane Risk of Bias v2. GRADE evidence assessment.

What this study cannot tell us

Focused on cardiovascular-risk populations. Pooled oral and subcutaneous semaglutide. Non-serious AEs may be underreported. Follow-up durations varied.

How to read the evidence

Exemplary methodology: 50 RCTs, TSA confirmation, Cochrane RoB2, GRADE assessment. Highest quality safety evidence available for semaglutide.

When this study was published

Published in 2025; literature through March 2025.

The bigger picture

This analysis resolves uncertainty about semaglutide's net benefit-risk profile. The mortality reduction clearly outweighs the increased GI side effects, but the 3-4x increase in nausea/vomiting highlights the importance of managing these symptoms for treatment adherence.

Questions still open

Do GI side effects diminish with longer-term use?
Which semaglutide formulation (oral vs SC) has a better GI side effect profile?
Can prophylactic anti-nausea strategies improve semaglutide adherence?

Common questions

Is semaglutide safe?

Yes, overall. This analysis of nearly 55,000 patients shows semaglutide reduces death by 15% and reduces serious adverse events. The main trade-off is a significant increase in nausea (3x), vomiting (4x), and diarrhea (1.9x), which are mostly non-serious but can affect quality of life and treatment adherence.

Do the benefits of semaglutide outweigh the side effects?

Based on this analysis, clearly yes. The life-saving benefits (15% mortality reduction, fewer heart attacks) far outweigh the non-serious GI side effects. However, managing nausea and vomiting is important for patients to stay on the medication and realize these benefits.

Read the original research

The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.

BMC medicine, 23(1), 654

View on PubMed ↗Publisher’s paper ↗

Citation

Sillassen, Christina Dam Bjerregaard; Petersen, Johanne Juul; Faltermeier, Pascal; Yucel, Delal; Siddiqui, Faiza; Andersen, Rebecca Kjær; Graever, Leonardo; Bjerg, Jonas Leth; Kamp, Caroline Barkholt; Grand, Johannes; Dominguez, Helena; Frølich, Anne; Gæde, Peter; Gluud, Christian; Mathiesen, Ole; Jakobsen, Janus Christian. (2025). The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.. BMC medicine, 23(1), 654. https://doi.org/10.1186/s12916-025-04486-0